Medicines Access Programs (MAP) are programs offered by pharmaceutical companies (sponsors) to facilitate deferred cost, cost-free or subsidised access to medicines for hospital patients before the implementation of relevant funding arrangements.
MAP include, but are not limited to, the following:
- Compassionate Use
- Expanded Access Programs
- Product Familiarisation Programs (also known as patient familiarisation programs ) (PFPs)
- Cost-Share Programs
The following documents can be used to assist in fulfilling the Guiding Principles for the governance of Medicines Access Programs in Australian Hospitals issued by CATAG available here.
It is recommended that MAPs have standard criteria for decision-making by DTCs. The following documents are recommended for use by the DTC when participating in a MAP.
It is recommended by the CATAG Guiding Principles for Medicines Access Programs in Australian Public Hospitals that MAP reports from prescribers are collated by the DTC.
NSW TAG acknowledges the Western Australian Therapeutics Advisory Group in the development of these forms.
Page last updated 1 July 2020